Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com

Resources

Browse and download available Oncotype DX test resources for you and your patients.

A leading physician describes how the AR-V7 Nucleus Detect® test helped him make a personalized treatment decision for his mCRPC patient after the patient failed an AR-targeted therapy.

AR-V7 testing in mCRPC: A case study
A leading physician describes how the AR-V7 Nucleus Detect® test helped him make a personalized treatment decision for his mCRPC patient after the patient failed an AR-targeted therapy.

Leading physicians share insights into mCRPC disease management and how they navigate the rapidly evolving treatment landscape in advanced prostate cancer.

How do you manage mCRPC patients?
Leading physicians share insights into mCRPC disease management and how they navigate the rapidly evolving treatment landscape in advanced prostate cancer.

Listen to leading physicians discuss the NCCN guidelines® updates and how they incorporate these into their practices for patient management in mCRPC.

Overview of the redesigned low-risk report for the Oncotype DX GPS Assay
Dr. Daniel Shoskes, MD, (Field Medical Director of Urologic Oncology Medical Affairs) provides an overview of the redesigned Oncotype DX GPS report for clinically low-risk prostate cancer.

Learn what top physicians look for to help determine AR-targeted therapy failure.

How do you define AR-targeted therapy failure?
Learn what top physicians look for to help determine AR-targeted therapy failure.

Your patient fails an AR-targeted therapy. What's next? Leading physicians share insights into how they determine next treatment.

mCRPC treatment management post AR-targeted therapy failure
Your patient fails an AR-targeted therapy. What's next? Leading physicians share insights into how they determine next treatment.

Find out how AR-V7 testing helps physicians guide treatment decisions for their mCRPC patients based on easy to interpret results.

Introduction to the Clinically High-Risk Report for the Oncotype® DX GPSAssay
Dr. Rick Baehner discusses the new Oncotype® DX GPS assay report for clinically high-risk prostate cancer patients

Learn what top physicians look for when sequencing therapies in mCRPC patients.

Sequencing therapies in mCRPC patients
Learn what top physicians look for when sequencing therapies in mCRPC patients.